DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Glucagonis the generic ingredient in five branded drugs marketed by Lilly, Eli Lilly And Co, Xeris, Novo Nordisk, and Fresenius Kabi Usa, and is included in six NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Glucagon has fifty-eight patent family members in thirty-one countries.
There are twelve drug master file entries for glucagon. One supplier is listed for this compound.
Summary for GLUCAGON
|Drug Master File Entries:||12|
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||14|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for GLUCAGON|
|DailyMed Link:||GLUCAGON at DailyMed|
Recent Clinical Trials for GLUCAGON
Identify potential brand extensions & 505(b)(2) entrants
|Translational Research Institute for Metabolism and Diabetes, Florida||Phase 2|
|Adrian Vella||Phase 3|
|Steno Diabetes Center Copenhagen||Phase 2|
Pharmacology for GLUCAGON
|Drug Class||Antihypoglycemic Agent |
Gastrointestinal Motility Inhibitor
|Physiological Effect||Increased Gluconeogenesis |
Decreased GI Smooth Muscle Tone
Decreased GI Motility
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Eli Lilly And Co||BAQSIMI||glucagon||POWDER;NASAL||210134-001||Jul 24, 2019||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Xeris||GVOKE HYPOPEN||glucagon||SOLUTION;SUBCUTANEOUS||212097-004||Sep 10, 2019||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Eli Lilly And Co||BAQSIMI||glucagon||POWDER;NASAL||210134-001||Jul 24, 2019||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Xeris||GVOKE HYPOPEN||glucagon||SOLUTION;SUBCUTANEOUS||212097-004||Sep 10, 2019||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.